ADMA FY 2023 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$258M+67.6% YoY

Gross Profit

$89M34.4% margin

Operating Income

$22M8.4% margin

Net Income

-$28M-10.9% margin

EPS (Diluted)

$-0.13

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$4M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$329M

Total Liabilities

$194M

Stockholders' Equity

$135M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$258M	$154M	+67.6%
Gross Profit	$89M	$35M	+152.2%
Operating Income	$22M	-$39M	+155.0%
Net Income	-$28M	-$66M	+57.2%